| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 24 Mar 2026 | 19 Mar 2026 |
| Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/03/2026 inter alia to consider and approve the second & final Call and fixation of Record date by the Rights Issue Committee at their Meeting. Solara Active Pharma Sciences Limited has informed the Exchange that the Rights issue committee members at its meeting held on March 24, 2026, has approved the making of Second & Final call of ? 112.50/- per equity shares (? 3.00/- towards face value and ? 109.50/- towards securities premium) per Rights Share in respect of partly paid Rights Shares and Fixed the Record date as April 02, 2026 for the same. (As per BSE Announcement dated on: 24.03.2026) | ||
| Board Meeting | 6 Feb 2026 | 30 Jan 2026 |
| Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 inter alia to consider and approve unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended December 31 2025. Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, the unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025 along with the Limited Review Report for the said period. (As per BSE Announcement dated on: 06.02.2026) | ||
| Board Meeting | 17 Dec 2025 | 17 Dec 2025 |
| Solara Active Pharma Sciences Limited has informed the Exchange regarding Board Meeting held on December 17, 2025 inter alia to consider appointment of Mr. Mohanraj. S (DIN:08420411) as Additional Executive Director and Whole Time Director Solara Active Pharma Sciences Limited has informed the exchange regarding allotment of 1,500 shares pursuant to exercise of ESOP options. | ||
| Board Meeting | 5 Nov 2025 | 29 Oct 2025 |
| Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2025 inter alia to consider and approve unaudited financial results of the Company for the quarter and half year ended September 30 2025. Solara Active Pharma Sciences Limited has informed the Exchange regarding the Inter alia, to consider and approve the Unaudited Financial Statements for the quarter and half year ended September 30, 2025 alongwith the Limited Review Report for the said period. (As Per BSE Announcement Dated on:05.11.2025) | ||
| Board Meeting | 25 Jul 2025 | 18 Jul 2025 |
| Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/07/2025 inter alia to consider and approve unaudited standalone and consolidated Financial Results for the quarter ended June 30 2025 Solara Active Pharma Sciences Limited has informed the Exchange regarding inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025 along with Limited review Report for the said period (As Per BSE Announcement Dated on: 25.07.2025) | ||
| Board Meeting | 15 May 2025 | 7 May 2025 |
| Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2025 inter alia to consider and approve Audited standalone and consolidated Financial Results for the quarter and year ended March 31 2025 Solara Active Pharma Sciences Limited has informed the Exchange regarding the Appointment of Internal, Secretarial Auditor and Reappointment of Cost Auditor in the Board Meeting held on May 15, 2025 (As Per BSE Announcement Dated on: 15.05.2025) | ||
| Board Meeting | 2 Apr 2025 | 26 Mar 2025 |
| Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/04/2025 inter alia to consider and approve the First Call money Notice on the partly paid Equity Shares issued on Rights basis which is to be sent to the eligible Shareholders Solara Active Pharma Sciences Limited informed the exchange about the outcome of the Rights Issue Committee Meeting held today (i.e.) April 02, 2025 interalia to consider and approve the First call money notice to be sent to the eligible shareholders Outcome: Solara Active Pharma Sciences Limited informed the exchange about the Rights Issue Committee Meeting held today (i.e.) on April 02, 2025 interalia to consider and approve the First call money notice to be sent to the eligible shareholders (As per BSE Announcement Dated on 02/04/2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
